Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study

Fineline Cube Nov 27, 2024

UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...

Company Drug

Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA

Fineline Cube Nov 27, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry

Fineline Cube Nov 27, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...

Company Deals Policy / Regulatory

AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan

Fineline Cube Nov 27, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Company Drug

Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study

Fineline Cube Nov 27, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...

Company Deals

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation

Fineline Cube Nov 27, 2024

China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology...

Company Drug

Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC

Fineline Cube Nov 27, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...

Company Deals

Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal

Fineline Cube Nov 26, 2024

US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies,...

Company Medical Device

Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment

Fineline Cube Nov 26, 2024

Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...

Company Deals

Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services

Fineline Cube Nov 26, 2024

US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian...

Policy / Regulatory

NHSA to Announce NRDL Adjustment Results at November 28th Press Conference

Fineline Cube Nov 26, 2024

The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...

Policy / Regulatory

NMPA and Local Governments Streamline Drug Approval Processes in China

Fineline Cube Nov 26, 2024

The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...

Company Deals

Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline

Fineline Cube Nov 26, 2024

Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...

Company Medical Device

Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System

Fineline Cube Nov 26, 2024

US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...

Company Deals

Boston Scientific Corporation to Acquire Intera Oncology Inc., Expanding Cancer Treatment Portfolio

Fineline Cube Nov 26, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement...

Company Drug

Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo

Fineline Cube Nov 26, 2024

China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...

Company Drug

GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review

Fineline Cube Nov 26, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...

Company Drug

Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939

Fineline Cube Nov 26, 2024

China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...

Company Drug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

Fineline Cube Nov 26, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...

Posts pagination

1 … 254 255 256 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.